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In the present study it is shown that poloxamer 188, added before or immediately after an electrical pulse used for electroporation,
decreases the number of dead cells and at the same time does not reduce the number of reversible electropores through which
small molecules (cisplatin, bleomycin, or propidium iodide) can pass/diﬀuse. It was suggested that hydrophobic sections of
poloxamer 188 molecules are incorporated into the edges of pores and that their hydrophilic parts act as brushy pore structures.
The formation of brushy pores may reduce the expansion of pores and delay the irreversible electropermeability. Tumors were
implanted subcutaneously in both ﬂanks of nude mice using HeLa cells, transfected with genes for red ﬂuorescent protein and
luciferase. The volume of tumors stopped to grow after electrochemotherapy and the use of poloxamer 188 reduced the edema
near the electrode and around the subcutaneously growing tumors.
1.Introduction
Cancer remains a leading cause of mortality despite the
advances in its understanding, detection, and treatment. The
use of high-voltage electrical pulses causes the formation of
pores in cell membranes and thus increases the uptake of
moleculeslikesugars,drugs,proteins,andDNAintocells[1–
5].
The cell membranes are reversibly or irreversibly (necro-
sis, rupture) porated at given electrical parameters, as ﬁeld
strength and duration of pulses. The electroporation has
been used to enhance the delivery of chemotherapeutic
drugs like cisplatin and bleomycin in cancer cells and
solid tumors, respectively. This application has been termed
electrochemotherapy [6–9]. Its eﬀectiveness is caused by
increased uptake and accumulation of anticancer drugs into
reversibly electroporated tumor cells. Side eﬀects in terms
of an acute inﬂammatory response have been thoroughly
described after electrochemotherapy of animals tumors [10–
19].However,fortheelectrochemotherapyofhumantumors
the resulting secondary injury eﬀects have not published in
detail. Glass et al. [20]a n dR e b e r s e ke ta l .[ 21] have shown
that local side eﬀects such as erythema and edema occurred
at the treatment site after electrochemotherapy of human
neoplasias and that these lesions disappeared within a period
of 2–4 weeks. Peycheva et al. [8] have used a lower ﬁeld
strength for the electrotreatment of Mycosis fungoides to
avoidpossibleskinnecrosisorerythemawhenhumanlesions
were in body regions with tender skin. The use of low ﬁeld
intensitytoavoidsideeﬀectsenforcesandrequiresmorethan
one electroprocedure [8].
For this reason experimental conditions have been
sought, which would diminish the number or extent of such
side eﬀects. Poloxamer 188 (MW 8.4 kDa), poly(ethylene
oxide)-poly(propylene oxide)-poly(ethylene oxide), is a
water soluble triblock copolymer, a nonionic nontoxic sur-
factant, consisting of approximately 150 hydrophilic (∼80%)
and 30 hydrophobic monomers with a total length of 300 ˚ A.
The surfactant monomer is biologically active and has been
used for diﬀerent clinical and biological applications and
could, for example, be a candidate to reduce the secondary
injury eﬀects [22, 23].2 Journal of Biomedicine and Biotechnology
To that end poloxamer 188 (P188) has been used to
“seal” cells against the loss of carboxy-ﬂuorescein dye after
electroporation, to protect skeletal muscle cells after heat
shock and against death due to loss of membrane integrity
caused by neurotoxic eﬀects [22–24]. Recently, P188 (which
is >80% polyethylene glycol (PEG)) has been described as
a “free radical scavenger” [25, 26]. Poloxamer 188 has been
investigated by diﬀerent physicochemical approaches on
monolayer and bilayer membranes [27], but the mechanism
of its action is not clear [28].
Inthepresentstudyitisshownthatpoloxamer188added
during or immediately after the electrical pulse used for elec-
troporationreducesthenumberofdeadcellsandatthesame
time does not block the formation of reversible electropores
through which small molecules such as anticancer drugs
(cisplatin, bleomycin) or propidium iodide can pass/diﬀuse.
The use of P188 did not block electrochemotherapy with
cisplatin of tumors implanted into nude mice.
2.MaterialsandMethods
2.1. Chemicals. Poloxamer 188 named also Pluronik F68NF
was from BASF Corporation (USA), Cisplatin from Medac,
Germany,andBleomycinfromEuroNipponKayakuGMBH,
Germany.
2.2. Cell Lines. The human breast adenocarcinoma cell
line MDA-MB-231 was obtained from the American Type
Cultural Collection (HTB-26) and grown as monolayer
in RPMI-1640 medium supplemented with 10% fetal calf
serum (FCS) and 2mM L-glutamine. All cell lines were
maintained at 37◦C in an incubator with humidiﬁed atmo-
sphere containing 5% CO2 and were routinely passaged
when 80–85% of cells were conﬂuent using 0.25% trypsin
and 0.02 EDTA (Invitrogen, Karlsruhe, Germany).
SKW-3 (DSMZ no. ACC 53, human chronic T-cell
leukemia) and Jurkat cell lines (human acute T-cell
leukemia) were also used. Both cell lines were grown as
suspension cultures (RPMI-1640 medium, with 10% FCS
and 2mM L-glutamine) at the same conditions as described
above. Cells were passaged two or three times per week to
keep them in log phase.
Erythrocytes Venous blood erythrocytes from healthy
donors were collected in a medium (150mM NaCl, 5mM
EDTA, pH 7.4), then washed in 150mM NaCl, 10mM TRIS-
HCl, pH 7.4, and for 3 times in 230mM sucrose, and ﬁnally
resuspended in 230mM sucrose, 10mM TRIS-HCl, pH 7.4,
at a concentration of 109cells/ml.
Nude Mice were obtained from Charles River (Sulzfeld,
Germany) and maintained in a minibarrier system. They
received food (Altromin) and autoclaved water. Two tumors
were implanted subcutaneously in both ﬂanks of the mice
using a suspension (105cells) of a HeLa cell subclone. These
cells are stably transfected with plasmids for red ﬂuorescent
protein (RFP) and luciferase. Mice weighing about 25g at
an age of 6 to 8 weeks were used in the experiments. 30
tumorswereusedintotal.Tumorsgrowntoasizeof5–7mm
in diameter were used in the experiments. Visualisation of
the tumors was done by an IVIS imaging system and given
in p/sec/cm2/sr (the number of photons per second that
leave a square centimeter of tissue and radiate into a solid
angle of one steradian). DsRed is a red ﬂuorescent protein
(excitation wave length 500–550nm, emission wave length
575–650nm) and luciferase is an enzyme which cleaves
the substrate luciferin. Before acquiring the luminescent
image, a luciferin solution was injected into the animals
intraperitoneally (i.p). Following cleavage, luciferin also
emits photons which are then registered by the IVIS camera.
In the case of luciferase/luciferin the images were taken
maximally 10 minutes after i.p. injection of luciferin.
The tumor volume (V0) was calculated according to the
formula V0 = axb2/2, (a ≤ b), where a and b are the
tumor length and width. The diameters of the lesions were
measured by a caliper.
2.3. Electroporation Protocol. MDA-MB-231, Jurkat and
SKW-3 cells (100μlw i t h5 ·105 cells) were electroporated in
0.3M mannitol, 0.1mM Ca acetate and 0.1mM Mg acetate.
The sample chambers (Bio Rad Laboratories, Richmond,
CA) were equipped with ﬂat parallel electrodes, with elec-
trode distance d = 0.4cm. The cell suspension was treated
with one rectangular electrical pulse with 5ms duration. The
eﬀective ﬁeld strength E0 = U0/d(V · cm−1), where U0 is
the electric voltage in V, was in the range of 1.0kV · cm−1.
P188 at concentration 0.1, 0.5 or 1.0mM was added during
or after the electroporation. After the electrical treatment,
900μl RPMI-1640, supplemented with 10% FCS, was added
to each sample. The controls were treated under the same
conditions but without the application of an electrical pulse.
MTT Assay for Cells Survival (MTT Test). Cells were seeded
in 96-well plates (ﬂat tissue bottom, Becton Dickinson, Hei-
delberg, Germany) at a density of 5·104 cells per 100μl/well
after the electroporation. The ﬂat tissue bottoms were placed
at 37◦C in an incubator with humidiﬁed atmosphere and 5%
CO2 for 24 hoursours (h). For each treatment, at least 8 wells
were used. The cell viability fraction was determined by the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) dye-reduction assay, as described by Mosmann
[29] with some modiﬁcations [30]. In brief, after the
incubation period with the test compounds, MTT-solution
(10 mg/ml in PBS) was added (10μl/well). Plates were
further incubated for 4 hours at 37◦C and the formazan
crystalsformedweredissolvedbyadding110μl/wellacidiﬁed
2-propanol (0.04 N HCl). Absorption was measured by
an automated microtiter plate spectophotometer (Anthos,
2001) at 540nm, reference ﬁlter at 690nm. Complete
medium (100μl), MTT stock (10μl) and 0.04N HCl in 2-
propanol (110μl) was used as photometric control.
Flow Cytometry Analysis (FACS)—Detection of Electroperme-
abilisation. Propidium iodide (PI), nonpermeate ﬂuorescent
dye,becomesdetectableafterenteringintothepermeabilised
and/or damaged cells. FACS analysis was done immediately
after every one treatment (less then 5 minutes). The PI
was added in the suspension before or after the applicationJournal of Biomedicine and Biotechnology 3
of the electrical pulse at a ﬁnal concentration of 100μM.
The percentage of permeabilised cells and mean ﬂuorescence
intensity were determined from the histogram obtained by
ﬂow cytometry (FACS Calibur, Becton Dickinson, USA)
according to the protocol given by Pucihar et al. [31]. On the
histogramoftheelectrotreatedprobe,theposition ofthetwo
markers(M1and M2)wasselectedattheapparentboundary
between the population of nonpermeabilised (M1) and
permeabilised cells (M2). The position of the markers was
kept the same for all investigated parameters in the frame
of one experiment. Intact cells of the control sample were
approximately80–95%.Thenumberofcountedcellswasnot
less than 20000 per sample.
Electrohaemolysis. HaemolysiswasdoneaccordingtoTomov
[32]withmodiﬁcation. Anerythrocytes’suspension(0.3ml)
was poured into a BioRad cuvette with ﬂat Al electrodes,
distance 0.2cm. Electrohaemolysis was obtained by the
application of one rectangular pulse of 3kV · cm−1 with a
duration of 0.5ms. The chamber was washed three times
with medium (230mM sucrose, 10mM TRIS-HCl, pH 7.4)
and then the total erythrocytes’ suspensions were incubated
on ice for a given time (1–5 hours) and then centrifuged. The
collected supernatant was analyzed spectrophotometrically
at 540nm. The extent of erythrocyte lysis was deﬁned as a
ratio (in percent) between the extinction of electroporated
erythrocytes and that of erythrocytes haemolysed by distil-
lated water (100% lysis).
Electrochemotherapy of Tumors. The animal studies were
approved by the responsible authority for animal ex-
periments (Regierungspraesidium Karlsruhe). In case of
chemotherapy 150μl (0.5mg/ml) cisplatin were injected
intraperitoneally (i.p.) two times during the ﬁrst week of
treatment. Electrochemotherapy predominantly is a single-
act procedure which was carried out as follows: First 50μlo f
1%lidocainewasinjectedintothetumorand,usingthesame
needle, 50μl (0.5 mg/ml) cisplatin was administered into the
tumor 5 minutes later. Then electrical pulses were applied
ﬁve minutes after the injection of cisplatin. P188 in 0.5ml
RPMI medium (at 0.1mM concentration) was injected i.p. 5
min after electrochemotherapy. The concentration of P188
was based on the assumption that the extracellular ﬂuid
volume equals about 24% of the total body weight [33].
For tumor electrochemotherapy a new electroporator
generating biphasic pulses had been developed because
these are more eﬃcient and better tolerable to the patients.
The instrument is equipped with a large voltage control
in the limits of 100–2200V, simpliﬁed operations, locking
against illegal manipulations, a battery supply, enhanced
protection against electrical hazards both for the patient
and the physician, autonomy providing for more than 200
electroporations with one battery charge, and a recharging
time for a depleted battery of less than 10 hours. The weight
of the apparatus is about 3kg. The electrochemotherapy
with cisplatin was carried out with series of 8 biphasic
pulses, each of them with 50μs +5 0 μs duration and
pause of one ms between them, thus the total duration
of the series reached 7.8ms. The use of biphasic electrical
pulse sequence was introduced for electrochemotherapy,
because this procedure resulted in improved eﬃciency and
tolerability by the patients (as determined by the reduction
of muscle’s contractions) [34]. Optimal contact with skin
was ensured with the aid of an electroconductive gel. The
ﬁeld strength for electrochemotherapy was 1200V · cm−1.
The electrodes were a pair of parallel stainless steel wires of
0.8mm in diameter and 15mm of length. The interelectrode
distance was adjustable (caliper type) in the range of
5–30mm.
3. Results
3.1. Viability of Cells by MTT Test. Viability of MDA-MB-
231 cells was checked by MTT test (cytotoxic or therapy
test), which gave the percentage of irreversibly porated
cells after the application of one rectangular electrical pulse
with 5ms duration and 1kV · cm−1 ﬁeld intensity with or
withouttreatment(Figure 1). MTT was added 24 hours after
the treatment. Experiments connected with MTT test were
carried out to ﬁnd the best conditions for the electrodelivery
of anticancer drugs into the cells. We sought to establish
conditions following which the electroloading of cells with
drugs would be carried out in cells which in their majority
were not irreversibly damaged. In this case, the electrical
parameters were such that the irreversibly porated cells
amountedto20–25%oftotalcells.Poloxamer188wasadded
before or immediately after the electrical pulse application.
The number of surviving cells increased by 15% up to
90% compared with the electroporated control, if P188 was
present during the pulse. The use of poloxamer 188 at the
same concentration but added after the pulse increased the
number of surviving cells by additional 4% up to near 95%.
The share of destructed cells (probably dead by apoptosis)
following exposure to 10μM cisplatin (without pulse) was
26% and after additional electroporation increased by two
times. Additional exposure to P188 increased the share of
dead cells to about 65%, regardless whether electroporation
was done before or after adding P188.
Bleomycin is an antibiotic that does not pass through the
intact membrane by passive diﬀusion. The cytotoxic eﬀect of
bleomycin administered together with a pulse was 60% and
reached even 70% in the presence of P188 (added before or
after the pulse).
From the data given in Figure 1 it is obvious that
poloxamer 188 does not block electroloading of cells with
anticancer drugs as cisplatin or bleomycin. On the contrary,
the presence of this polymer during the pulse or added after
the electrotreatment increased the number of dead cells in
response to the two cytotoxic agents. Similar results were
obtained by MTT test with SKW-3 and Jurkat cells following
application of one pulse of 5ms duration and 1.0kV · cm−1
ﬁeld strength (data not shown).
3.2. Electropermeabilisation with Propidium Iodide and FACS
Analysis. The electropermeabilisation was followed by ﬂow
cytometry measurements with PI [31]. The dye was added4 Journal of Biomedicine and Biotechnology
0
20
40
60
80
100
120
V
i
a
b
i
l
i
t
y
(
%
)
C
o
n
t
r
o
l
C
o
n
t
r
o
l
+
p
C
i
s
p
l
a
t
i
n
B
l
e
o
m
y
c
i
n
+
p
+
P
1
8
8
+
p
+
I
P
1
8
8
+
p
+
c
i
s
p
l
a
t
i
n
+
p
+
c
i
s
p
l
a
t
i
n
+
P
1
8
8
+
p
+
c
i
s
p
l
a
t
i
n
+
I
P
1
8
8
+
p
+
b
l
e
o
m
y
c
i
n
+
p
+
b
l
e
o
m
y
c
i
n
+
P
1
8
8
+
p
+
b
l
e
o
m
y
c
i
n
+
I
P
1
8
8
Figure 1: MTT test of treated MDA-MB-231 cells at 24 hoursours
after treatment; 5·105 cells suspended in 100μlo fab u ﬀer (0.3M
mannitol, 0.1mM Ca acetate and 0.1mM Mg acetate) were
electroporated according to the following electrical parameters:
ﬁeld strength 1.0kV · cm−1 and one rectangular pulse with a
duration of 5ms. Cisplatin was used at 10μM and bleomycin—at
20μM concentration. +p indicates electroporated probes, +P188
indicates that cells were electroporated in the presence of 0.1mM
P188, and +|P188 (0.1mM) indicates the addition of P188 after the
electrical pulse. All probes were diluted under identical conditions.
The data represent the mean values from three experiments.
at 100μM concentration to the cell suspension containing
5·105 cells (12·109 PI molecules per cell). The fraction of
electropermeabilised cells is the percentage within the M2
marker (Figures 2–4).
The electropermeabilisation state of MDA-MD-231 cells
is shown in Figure 2. The nonpermeable cells of the control
(non treated cells) in the M1 fraction (Figure 2(a))w e r e
approximately80%andintheM2fractionwere20%.Cellsin
M2 in the electroporated control were 93% (Figure 2(b)). A
similar number of permeable cells in M2 was found (Figures
3(d), 3(f) and 3(h)), when the electropermeabilisation was
done in the presence of P188 (0.1, 0.5 and 1.0mM). The
number of permeable cells in M2 is nearly equal in all probes
containing poloxamer 188, ranging from 0.1 to 1.0mM
(12·109–12·1010 molecules per cell).
In the case when PI was added within one minute after
the pulse, the cells in M2 were reduced by 4% (Figure 2(c)).
The mean value of electropermeability was about 90% and it
was reduced by 3–7% as compared with the samples where
PI was present during the pulse. Practically, the permeability
of the cells for PI was not considerably changed when P188
was added before or after the pulse (Figures 2(d)–2(i)).
The ﬂow cytophotometric behavior of the two other
types of cells (SKW-3 and Jurkat) is shown on Figures 3 and
4. The data about the permeabilisation state in all variants of
treatment are similar to these given in Figure 2.
The data from experiments carried out by FACS analysis
(Figures 2–4) show that P188 added during or after the pulse
did not block the formation of small electropores through
which small molecules are able to pass, like PI, or cisplatin
and bleomycin, respectively. The eﬀects were not dependent
on the concentration of P188 (Figures 2–4).
3.3.Electrohaemolysis. Thekineticsofhaemolysisafterappli-
cation of one rectangular pulse of 3kV · cm−1 (duration of
0.5ms) in the presence of a very low concentration of P188
(10μM) is shown in Figure 5. Each point reﬂects the ratio
between electroporated erythrocytes (erythrocytes alone, in
the presence of P188 or P188 is added after electroporation)
and erythrocytes haemolysed by distillated water (100%
lysis). The percentage of erythrocytes haemolysed within
one hour was 40% and reached 95% after 5 hours. When
electroporationwasdoneinthepresenceofP188,haemolysis
after one hour was 22% and after 5 hours 60%, while when
P188 was added after the electrotreatment the extent of
haemolysis was 38% after one hour and reached a plateau
of about 60% after 2 hours. The protective eﬀect of P188 was
less clear if the compound was added after electroporation,
however after 5 hours the extent of haemolysis was 60% for
both exposure modalities (Figure 5).
The dependence of electrohaemolysis on the concentra-
t i o n so fP 1 8 8a f t e r3h o u r si sg i v e ni nFigure 6. Experimental
conditions for the electroporation (ﬁeld strength of 3kV ·
cm−1 and 1 pulse with a duration of 0.5ms) were such
that the extent of the irreversibly damaged erythrocytes
was high. The number of electrohaemolysed (irreversibly
electroporated) cells was reduced with the increase in the
concentration of P188.
3.4. Electrochemotherapy of Xenografts. The changes in
tumor growth after the various treatment arms are shown
in Figure 7. Chemotherapy with cisplatin reduced the tumor
volume by 50% compared with untreated controls (not
signiﬁcant).Theelectrotreatmentmodes(electrochemother-
apy or electrochemotherapy + P188) stopped the tumor
growth within the observation period of 30 days. This
corresponds to a tumor growth inhibition of more than 90%
comparedtountreatedcontrolsandishighlysigniﬁcant.The
diﬀerences in tumor growth were analysed by the Kruskal
Wallis test and found signiﬁcant for the two electroporation
groups.
Figure 8 shows the pictures of two representative cases
of tumors: Untreated control (mouse to the right) and
after electrochemotherapy with cisplatin and concomitantly
i.p. intraperitonially injected P188 (mouse to the left).
In our case there are small diﬀerences in using DsRed
(red ﬂuorescent protein) and luciferase signals. Luciferase
detection gave a stronger signal, permitting the detection of
small tumors, whereas Ds Red was preferable in the case of
big tumors, because with big tumors, the strong luciferase
signals might overlap.
According to WHO (World Health Organisation) guide-
lines the treatment response has to be evaluated at least 4
weeks after the therapy and a complete response is achieved
only in the absence of any trace of tumor at that time. The
tumors stopped to grow but were not in complete response
within the frame of the observation period of one month.
Some edema was observed around the tumors in response
to electrochemotherapy. The use of P188 reduced the skin
edema near the electrode and around the subcutaneously
growing tumors, which occurred during the ﬁrst days after
treatment.Journal of Biomedicine and Biotechnology 5
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Figure 2: Flow cytometry of MDA-MB-231 cells. Experimental conditions: 5·105 cells per 100μl suspension of 0.3 M mannitol, 0.1mM Ca
acetate and 0.1mM Mg acetate. Field strength—1.0kV ·cm−1, one pulse with a duration of 5ms. 100μM propidium iodide (PI) was added
during the pulse or after it; (a) nonporated control with PI added; (b) porated control with PI added before the pulse; (c) porated control
with PI added after the pulse; (d) and (e) 0.1mM, (f) and (g) 0.5mM, (h) and (i) 1.0mM poloxamer 188 and 100μM PI added; (d), (f) and
(h) are samples electroporated in the presence of poloxamer 188 and PI; (e), (g) and (i) poloxamer 188 and PI were added after the pulse.
The M1-marker represents the nonpermeable cells and the M2-marker—the permeable cells.
4. Discussion
Up to date the copolymer P188 has been used for various
biologicalandmedicalpurposes[22–25].Thecriticalmicelle
concentration (CMC) for poloxamer 188 is 100mg/ml
according to Kabanov et al. [35] and 12.5–51.7 mg/ml
according to Alexandridis and Hatton [36]. In our experi-
ments P 188 was used at concentrations ranging from 0.01 to
1.0mM (0.084–8.4mg/ml). For in vitro membrane applica-
tions, P188 is typically used at concentrations below its CMC6 Journal of Biomedicine and Biotechnology
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Figure 3: Flow cytometry of SKW-3 cells. Other conditions are the same as in Figure 2.
[28]. We suppose that poloxamer 188 at the concentrations
used by us is in monomer form that corresponds to its
biologically active form.
The results in Figures 1–4 show that this copolymer did
not block the entrance of anticancer drugs with small sizes
from 300 to 1400Da as cisplatin or bleomycin, as well as
of propidium iodide if P188 was added during the pulse or
immediately after it.
Flow cytometry showed that the PI permeability is not
dependent on the increase in the concentration of P188
(Figures 2–4). The mean number of electropores per cell
is expected to be about 2.4·104 [5]. Liu-Snyder et al. [26]
have shown that ﬂuorescently decorated PEG binds to the
membrane surface of the cells but does not enter the
cytoplasm. We also suggest that the P188 molecules are
concentrated in the area near the cell surface. We suppose
that some molecules of P188 are inserted in the pore and
some are free in the suspension.
For the ﬁrst time Lee et al. [24] used the triblock
poloxamer 188 to “seal” cells after electroporation in the
frame of 30 minutes. We followed the kinetic of haemolysis
after the electrotreatment (1–5 hours). After 5 hours theJournal of Biomedicine and Biotechnology 7
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Figure 4: Flow cytometry of Jurkat cells. Other conditions are the same as in Figure 2.
number of irreversibly destroyed erythrocytes was equal
(Figure 4) but if P188 was added immediately after the pulse
the ﬁnal value was reached earlier (after 2 hours).
Photos et al. [37] have demonstrated that polymersome
vesicles, made from diblock copolymers of poly(ethylene
oxide-polybutadiene (PEG-PBD)) possess long-lasting small
pores after electroporation treatment. By using a modiﬁed
version of electroporation, the authors [37] inspired com-
parisonsofbrushyporesobservedbythemwiththestructure
of the nuclear pore complex, which selectively regulates the
transport of some proteins or molecules into the cell nucleus
by binding to the brush and decreasing the entropy. We have
observed some increase in viability if poration was done in
the presence of P188 (Figure 1). The diﬀusion of cisplatin,
bleomycin or PI into the cells was not blocked by the used
triblock polymer. We therefore suggest that P188 forms so
called “brushy pores”, similar to the diblock polymer [37],
that permit some small molecules to pass through the pores
or block the leakage of ions which are essential for cell
survival.8 Journal of Biomedicine and Biotechnology
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Figure 5: Altered haemolysis after the application of one rectan-
gular pulse of 3kV · cm−1 and duration 0.5ms in the presence
of 10μM poloxamer 188. +P188 indicates that erythrocytes were
electroporated in the presence of 10μM P188, and +|P188 (10μM)
indicates the addition of P188 after the electrical pulse.
On the basis of the experimental results (Figures 1–5)
we suggest the following mechanism of action of triblock
copolymer (Figure 9).
Poloxamer 188 consists of a 1 750Da average molecular
weight hydrophobic part (30 propylene oxide units) and a 6
650Da hydrophilic part (2 ×76 ethylene oxide units—about
80% of the total molecular weight). In monomer form the
total length of P188 is about 300 ˚ A. The hydrophobic section
of P188 could be inserted into the hydrophobic part of the
pore edges or into some defect part of an electroporated
membrane. Its free hydrophilic parts could act as a ﬂexible
brush in the hydrophilic pore allowing the diﬀusion of small
molecules into the cells. Due to the small hydrophobic part
of P 188 as compared with some membrane molecules
such as cholesterol showing a bigger size and more intense
hydrophobic interactions, this copolymer is eliminated from
pores and the membrane within 2–5 hours. Our data show
that the irreversible permeabilisation is in deed reduced
(Figures 1, 5, 6). The formation of brushy pores may
reduce the expansion of pores and delay the irreversible
electroporation. The reversible electropores, decorated with
P188 could be in long-lived state also. We have found some
diﬀerences in the kinetics of electrohaemolysis when the
electroporation was done in the presence of P188 (Figure 5).
A reduction of the colloid-osmotic lysis (the irreversible
electroporation) is less probable which could occur due
to the blocking of the osmotic pressure of big-molecular
weight components of the cytoplasm in the presence of
big molecules of this copolymer in the medium. The
concentration of haemoglobin in one erythrocyte is 5mM.
The concentration of P188 (0.1–1.0mM) was very low
compared with the concentration of huge molecules such as
haemoglobin in erythrocytes or proteins in general within
other cell types. The data in Figure 6 show the dependence
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Figure 6: Haemolysis of erythrocytes, electroporated in the pres-
ence of diﬀerent concentrations (μM) of P188 after 3 hours. The
electrical parameters were the same as in Figure 5. The abscissa is
in logarithmic scale, the point 0.01 corresponds to the control (zero
concentration of P188).
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Figure 7: Growth curves of HeLa tumors implanted in Nude
mice: control (without any treatment); chemotherapy with cis-
platin; electrochemotherapy with cisplatin injected intratumorally,
electrochemotherapy in the presence of P188 injected 5 minutes
afterpulsesintraperitoneally.Theobservedtimewas30days.Points
are mean value of three tumors. Standard errors are omitted due to
the overlap of the bars.
of electrohaemolysis (irreversible electroporation) on the
concentration of P188. This could suggest that some big
molecules that are not inserted in pores protect cells from
lysis or rupture by their adsorption onto the cell surface,
thus increasing the cellular membrane stability addition-
ally.
The edema after electrochemotherapy was reduced. It is
known that P188 can decrease the inﬂammation after elec-
tropermeabilisation and diﬀerent mechanical tissue injuries
by recruiting neutrophils and macrophages into damaged
areas [33, 38]. In the present study (in vivo and in vitro)Journal of Biomedicine and Biotechnology 9
25
20
15
10
5
×
1
0
9
Electrochemotherapy
with cisplatin +P188
Control
(Ds red labeling)
Image
Min =− 2.6344e +07
Max = 2.5054e +10
p/s/cm2/sr
Color bar
Min = 1.2527e +08
Max = 2.5054e +10
Bkg sub
Flat-ﬁelded
Cosmic
Click # MZ20090108192453
Thu, Jan 08, 2009 19 : 25 : 12
Level=High, Em=DsRed, Ex=DsRed
Bin: HR (4), FOV15, f4, 1s
Camera: IVIS 13203, S1620EEV
Series: Electrotherapy
Eperiment: Animals 21, 24
Label: DsRed
Comment:
Analysis comment:
(a)
25
20
15
10
5
×
1
0
9
Electrochemotherapy
with cisplatin +P188
Control
(Luciferin-luciferase labeling)
Image
Min =− 9.4238e +06
Max = 2.7403e +07
p/s/cm2/sr
Color bar
Min = 1.3702e +05
Max = 2.7403e +07
Bkg sub
Flat-ﬁelded
Cosmic
Click # MZ20090108192542
Thu, Jan 08, 2009 19 : 25 : 59
Filter: Open
Bin: HR (4), FOV15, f1, 1m
Camera: IVIS 13203, S1620EEV
Series: Electrotherapy
Eperiment: Animals 21, 24
Label: Luci
Comment:
Analysis comment:
(b)
Figure 8: Visualisation of the HeLa tumors by (a) red ﬂuorescence protein-Ds red and (b) luciferase/luciferin reaction by using an IVIS 100
system at 30 days after the ﬁrst electrotreatment.
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Figure 9: Scheme on the mechanism of P188 interaction in
biological membrane (explanation is given in the text).
we have shown that anticancer drugs can penetrate into
the electroporated cells in the presence of P188. Nude mice
are suitable animals for implanting human tumors but this
is due to their weak and delayed immune response. For
this reason the model used cannot predict the inﬂuence of
P188 on inﬂammatory processes such as secondary injury
eﬀects and the application of P188 in the human tumor
electrochemotherapy.
Electrochemotherapy is used as a method for treating
human and animals tumors [8, 10–21]. The use of P188
for pet cancer patients with spontaneous tumors is under
studies (Spugnini, E. and Tsoneva, I. unpublished data). The
use of P188 to reduce the inﬂammatory response of the
electrochemotherapy could be translated to humans.
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